Share
Mark Vignola
Korsana Biosciences, Inc., a company focused on discovering and developing therapies for neurodegenerative diseases, has appointed Mark Vignola, Ph.D., as Chief Financial Officer.
The appointment strengthens the company’s leadership team as it advances its pipeline and long-term growth strategy.
Dr. Vignola brings more than 15 years of experience in corporate finance within the biotechnology sector. He has a strong track record of leading financial and operational strategies that drive sustainable value creation and support business expansion. His expertise includes capital raising, investor relations, and guiding companies through key financial milestones.
Most recently, Dr. Vignola served as Chief Financial Officer at Terns Pharmaceuticals, where he led the company’s crossover financing, initial public offering, and multiple follow-on offerings. Prior to that, he was CFO at Applied Therapeutics, where he played a critical role in securing funding through several financing rounds to support clinical development programs.
Earlier in his career, Dr. Vignola held leadership roles at Intercept Pharmaceuticals, serving as Head of Corporate Development and Investor Relations. He also worked as a biotechnology equity research analyst at Needham & Company, gaining deep insights into capital markets and industry trends.
Dr. Vignola holds a B.S. in Biology from Boston College and a Ph.D. in Molecular Genetics and Microbiology from Duke University.
